Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

venetoclax 108Azacitidine 92Cytarabine 77Specimen Handling 52fludarabine 47Biopsy 38Daunorubicin 31Cyclophosphamide 31Injections 29Decitabine 29Idarubicin 27fludarabine phosphate 25Granulocyte Colony-Stimulating Factor 22Busulfan 22Whole-Body Irradiation 20Mycophenolic Acid 20Tacrolimus 18decitabine and cedazuridine drug combination 17Melphalan 17CPX-351 17Stem Cell Transplantation 16gilteritinib 14Mitoxantrone 14ivosidenib 13Filgrastim 13Peripheral Blood Stem Cell Transplantation 12Cladribine 12Magnetic Resonance Spectroscopy 11Etoposide 11Cyclosporine 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × sodium-iodide symporter × 90 days × Clear all
NCT03017820 2026-05-28

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

Phase 1 Recruiting
99 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡